Table 1.
Effect of CXCL1 expression level on survival of breast cancer patients.
| Type of Cancer | Expression Testing Method | Impact on Survival at High CXCL1 Expression | Number of Patients in the Study | Notes | Source |
|---|---|---|---|---|---|
| Breast cancer: ERα-positive breast cancer | qRT-PCR | Worse prognosis | 48 | RFS | [29] |
| Breast cancer: ERα-positive breast cancer | Microarray Kaplan–Meier Plotter database |
Better prognosis | 2061 | RFS Analysis based on the Kaplan–Meier Plotter database |
[31] |
| Breast cancer | IHC | Worse prognosis | 655 | OS, nuclear CXCL1 expression, at cytoplasmic CXCL1 expression there was only a trend (p = 0.08) |
[100] |
| Breast cancer | Microarray UALCAN/TCGA database |
Better prognosis | 1066 | OS, Analysis based on UALCAN |
[32] |
| Breast cancer | Microarray | Worse prognosis | 121 | OS | [34] |
| Breast cancer | Microarray Kaplan–Meier Plotter database |
Better prognosis | 3951/RFS 1402/OS |
OS, RFS analysis based on the Kaplan–Meier Plotter database |
[30] |
| Breast cancer | Microarray Kaplan–Meier Plotter database |
No significant impact on prognosis | 1402 | OS, trend of worse prognosis at high CXCL1 (p = 0.064), based on the Kaplan–Meier Plotter database |
[31] |
| Breast cancer | ELISA | Worse prognosis | 61 | OS, PFS circulating level of CXCL1 |
[38] |
| Breast cancer: basal breast cancer | Microarray Kaplan–Meier Plotter database |
Worse prognosis | 54 | OS, based on the Kaplan–Meier Plotter database |
[52] |
| Breast cancer | Microarray Finak microarray database |
Worse prognosis | 53 | RFS stromal CXCL1 expression based on Finak microarray database |
[37] |
ELISA—enzyme-linked immunosorbent assay; IHC—immunohistochemistry; OS—overall survival; PFS—progression-free survival; RFS—relapse-free survival; qRT-PCR—quantitative real-time polymerase chain reaction. Red color—worse prognosis, Blue color—better prognosis.